The Spanish biotechnology sector has always been at the forefront of innovation, speed and immediacy and has increasingly become a profitable business for both investors and entrepreneurs. Biotech companies have a great impact on the Spanish economy, contributing around 0.7% of Spanish GDP.
As a result, biotech research startups are growing rapidly, and investments in the sector are becoming more frequent and less high-risk.
Among the Spanish startups in the biotech sector are startups such as GoodGut, KeyZeel and eKuore, which seek to improve people's health by developing new technologies loan data applied to the healthcare sector.
Research into new solutions for diseases such as cancer or mobile applications that allow for optimizing healthcare services are undoubtedly startups with great growth potential.
The startup 24Genetics carries out diagnostic tests for genetic markers. With a presence in more than 100 countries, the biotechnology company markets seven different DNA tests (ancestry, nutrigenetics, pharma, health, sports performance, dermogenetics and talent and personality), with 100% of the tests carried out in a European laboratory using Illumina technology, one of the world leaders in genetic sequencing. 24Genetics is made up of an international team of proven scientific prestige and its tests are recognised by the National Centre for Biotechnology Information (NCBI).
Another biotech company with a promising future is KeyZell, which has just launched an innovative Artificial Intelligence system that aims to be the future of precision medicine in oncology, called KEYZELL OPS (Oncology Precision System). At the moment, it is only available for lung and breast cancer, but it promises to be a key tool in the fight against cancer, as it is capable of recommending to medical professionals the most appropriate treatments taking into account the individual characteristics of each patient and their type of cancer.
You may also be interested in: Profile, Functions and Tasks Performed by a Filmmaker
The tool would help oncologists make more precise decisions, allowing for personalized medicine, reducing recurrences, overmedication, hospitalization time, treatment costs, and, above all, improving the quality of life of patients.
